Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis

<p>Abstract</p> <p>Background</p> <p>This analysis of pooled data evaluates treatment outcomes of patients with schizophrenia receiving maintenance treatment with olanzapine long-acting injection (OLAI) by means of a categorical approach addressing the symptomatic and f...

Full description

Bibliographic Details
Main Authors:	Peuskens Joseph, Porsdal Vibeke, Pecenak Jan, Handest Peter, D'yachkova Yulia, Brousil Radim, Deberdt Walter
Format:	Article
Language:	English
Published:	BMC 2012-08-01
Series:	BMC Psychiatry
Online Access:	http://www.biomedcentral.com/1471-244X/12/130

Similar Items

Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection
by: Leslie Citrome
Published: (2009-11-01)

Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
by: Rosaria Di Lorenzo, et al.
Published: (2010-09-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-01-01)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
by: Heidi J. Wehring, et al.
Published: (2011-06-01)

Long-term functional improvements in the 2-year treatment of schizophrenia outpatients with olanzapine long-acting injection
by: Ascher-Svanum H, et al.
Published: (2014-06-01)

IVIVC from Long Acting Olanzapine Microspheres
by: Susan D'Souza, et al.
Published: (2014-01-01)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
by: JP Lindenmayer
Published: (2010-05-01)

Cost/effectiveness of aripiprazole vs. olanzapine in the long-term treatment of schizophrenia
by: Dutina Aleksandra, et al.
Published: (2019-01-01)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, I: analysis of cases
by: Stefaniak Victoria J, et al.
Published: (2010-06-01)

Post-injection delirium/sedation syndrome in patients with schizophrenia treated with olanzapine long-acting injection, II: investigations of mechanism
by: Stickelmeyer Mary, et al.
Published: (2010-06-01)

Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons
by: Ascher-Svanum H, et al.
Published: (2012-05-01)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
by: Katagiri H, et al.
Published: (2018-04-01)

Analysis of longitudinal data from the betaseron multiple sclerosis clinical trial
by: D’yachkova, Yulia
Published: (2009)

Analysis of longitudinal data from the betaseron multiple sclerosis clinical trial
by: D’yachkova, Yulia
Published: (2009)

Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
by: Detke Holland C, et al.
Published: (2012-05-01)

Early response predicts subsequent response to olanzapine long-acting injection in a randomized, double-blind clinical trial of treatment for schizophrenia
by: Stauffer Virginia L, et al.
Published: (2011-09-01)

Switching to olanzapine long-acting injection from either oral olanzapine or any other antipsychotic: comparative post hoc analyses
by: Ciudad A, et al.
Published: (2013-11-01)

Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia
by: Watson Susan B, et al.
Published: (2011-02-01)

Mesoporous Hydroxyapatite Particles as Olanzapine Carrier for Long-acting Delivery in Anti-depression Treatment
by: Lee, Cheng-Che, et al.
Published: (2013)

Correlation of Olanzapine or N-desmethyl-olanzapine Concentration with Therapeutic Outcomes in Patients with Schizophrenia
by: Pei-Ting Kuo, et al.
Published: (2014)

An unusual complication of a long-acting injectable antipsychotic: deep venous thrombosis caused by olanzapine pamoate
by: Serhat Tunç, et al.
Published: (2018-04-01)

The evaluations of risperidone and olanzapine in the treatment of schizophrenia disorders
by: Shu-Ling Chang, et al.
Published: (2010)

Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium
by: Macfadden Wayne, et al.
Published: (2011-04-01)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia.
by: Mong-Liang Lu, et al.
Published: (2016-01-01)

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder
by: Walter Deberdt, et al.
Published: (2008-09-01)

A 6-year open-label study of the efficacy and safety of olanzapine long-acting injection in patients with schizophrenia: a post hoc analysis based on the European label recommendation
by: An, et al.
Published: (2015-05-01)

Improvement of long-term outcome in schizophrenia: switching to risperidone long-acting injectable
by: Tzanakaki Maria, et al.
Published: (2006-02-01)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
by: Eduard Parellada, et al.
Published: (2012-01-01)

The Use of Long-Acting Injectable Antipsychotic Therapy for Schizophrenia
by: Jason Jiang, et al.
Published: (2018-09-01)

The management of schizophrenia: focus on extended-release quetiapine fumarate
by: Peuskens J
Published: (2011-09-01)

Effect of aripiprazole and olanzapine on the cognitive function in patients with schizophrenia
by: Xiao-Hong Wang
Published: (2020-05-01)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
by: Mohammad Zia Ul Haq Katshu, et al.
Published: (2018-01-01)

Safety and effectiveness of rapid-acting intramuscular olanzapine for agitation associated with schizophrenia – Japan postmarketing surveillance study
by: Katagiri H, et al.
Published: (2018-01-01)

Clinical outcomes with olanzapine long-acting injection: impact of the 3-hour observation period on patient satisfaction and well-being
by: Anand E, et al.
Published: (2016-10-01)

Amyloid as a depot for the formulation of long-acting drugs.
by: Samir K Maji, et al.
Published: (2008-02-01)

Recent Advances in Long-Acting Drug Delivery and Formulations
Published: (2023)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
by: Ita Fitzgerald, et al.
Published: (2021-09-01)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
by: Suneeta James, et al.
Published: (2016-01-01)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
by: Natalia N. Petrova, et al.
Published: (2020-12-01)

Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
Published: (2020-06-01)

Cannot write session to /tmp/vufind_sessions/sess_1b3bmtuji3b8u0govgick9cjhe